PITTSBURGH, May 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il. The purpose of the study was to determine if Predictive Oncology could lever ...

Predictive Oncology Inc. (NASDAQ:POAI) Q1 2024 Earnings Call Transcript May 15, 2024 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Operator Ladies and gentlemen, good morning, and thank you for standing by. Welcome to the Predictive Oncology Q1 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be an opportunity to ask your questions. Please be advised that today's co ...

Financial Performance - Predictive Oncology reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for Q1 2024, compared to a net loss of $3.4 million in Q1 2023[1][14] - Revenue for Q1 2024 was $419,646, representing a 75% increase from $239,895 in the same period of 2023[8][14] - Gross profit margin improved to approximately 55% in Q1 2024, up from 50% in Q1 2023, primarily due to a change in sales mix[8][14] - Basic and diluted net loss per common share for Q1 2024 was $(1.04), compared to $(0.86) for Q1 2023[8][14] Cash and Liabilities - The company ended Q1 2024 with $5.2 million in cash, down from $8.7 million as of December 31, 2023[8][11] - Total liabilities increased to $6.5 million as of March 31, 2024, compared to $6.1 million as of December 31, 2023[8][11] Expenses - General and administrative expenses increased to $2.6 million in Q1 2024 from $2.3 million in Q1 2023, mainly due to higher professional fees[8][14] Collaborations and Research - Predictive Oncology is collaborating with Fujifilm to enhance drug safety by improving bacterial endotoxin testing, utilizing its EndoPrep™ technology[4] - The company is making progress on a $6.2 million Phase 2b grant for a novel intranasal flu vaccine in collaboration with FluGen[4] - An abstract from a study with UPMC Magee-Womens Hospital has been accepted for presentation at the ASCO 2024 Annual Meeting, focusing on machine learning models predicting survival outcomes in ovarian cancer patients[4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 33-1007393 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 91 43rd Street, Suite 110 Pittsburgh, Pennsylvania 15201 (Address of ...

Financial Data and Key Metrics Changes - The company reported a net loss of $14.0 million for 2023, a decrease from a net loss of $25.7 million in 2022, indicating improved financial performance [16] - Revenue increased to $1.8 million in 2023 from $1.5 million in 2022, primarily driven by the Eagan operating segment [30] - Cash and cash equivalents decreased to $8.7 million as of December 31, 2023, down from $22.1 million in the previous year [30] Business Line Data and Key Metrics Changes - The Eagan operating segment contributed $1.135 million in revenue for 2023, up from $1.064 million in 2022, while the Pittsburgh segment increased to $493,000 from $359,000 [30] - Operating expenses decreased to $3.7 million in 2023 from $3.8 million in 2022, mainly due to lower research and development expenses [15] Market Data and Key Metrics Changes - The company highlighted its unique position in the artificial intelligence drug discovery market, leveraging a proprietary biobank of over 150,000 tumor samples and extensive drug response data [34] - The injectable drug market is projected to grow from $6 billion to $10 billion by 2034, indicating significant market opportunities for the company [37] Company Strategy and Development Direction - The company has restructured and repositioned itself over the past year, focusing on accelerating growth through its PEDAL platform and biobank capabilities [3][4] - The strategic vision includes leveraging proprietary data to aid drug development partners and enhance clinical trial designs [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made since implementing the new strategic vision, emphasizing the importance of partnerships and collaborations in driving future growth [32] - The company aims to mitigate risks in drug development by providing accurate predictions of tumor responses, which could significantly enhance the success rates of drug candidates [19][20] Other Important Information - The company has engaged in collaborations with various organizations, including Cvergenx and FluGen, to develop innovative solutions in drug discovery and vaccine development [26][37] - A proposal was submitted to the RK Mellon Foundation to enrich data sets necessary for modeling, which is crucial for future collaborations and drug development efforts [25] Q&A Session Summary Question: What is the company's outlook on drug development costs and risks? - The company noted that drug development is inherently expensive and risky, particularly in oncology, with only a small fraction of drugs selected for clinical trials ultimately receiving approval [43] Question: How does the company plan to utilize its data for clinical utility? - The company is exploring the possibility of reevaluating data to develop biomarker leads and new predictive models for various cancer types, as well as for drug repurposing and combinations [44]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission file number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) Delaw ...

EXHIBIT 99.1 Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug develop ...

Predictive Oncology Inc. (NASDAQ:POAI) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q3 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. And I would now like to hand the conference over to your speaker for today, Mr. Glen ...

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________________ to _________________________ Commission File Number: 001-36790 Predictive Oncology Inc. (Exact name of registrant as specified in its charter) | Delaware | 33-1007393 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 91 43r ...

Predictive Oncology, Inc. (NASDAQ:POAI) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-o ...